Cargando…

DLBCL 1L—What to Expect beyond R-CHOP?

SIMPLE SUMMARY: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin’s lymphoma. About two-thirds of patients are cured by the first-line (1L) standard of care (SOC), the R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone) immunochemotherapy pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stegemann, Maike, Denker, Sophy, Schmitt, Clemens A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946010/ https://www.ncbi.nlm.nih.gov/pubmed/35326604 http://dx.doi.org/10.3390/cancers14061453

Ejemplares similares

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
por: Lancman, Guido, et al.
Publicado: (2018)

Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL
por: Hartert, Keenan T., et al.
Publicado: (2020)

Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
por: Sun, Na, et al.
Publicado: (2015)

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response
por: Denker, Sophy, et al.
Publicado: (2019)

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
por: de Jonge, A. Vera, et al.
Publicado: (2023)

CYCLON and NPM1 Cooperate within an Oncogenic Network Predictive of R-CHOP Response in DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
por: Qiao, Li-Yan, et al.
Publicado: (2021)

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies
por: Ayed, Ayed O., et al.
Publicado: (2018)

Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP
por: Dong, Qian, et al.
Publicado: (2022)

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
por: Herrmann, Ken, et al.
Publicado: (2014)

Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement
por: Geng, Hongzhi, et al.
Publicado: (2023)

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL
por: Wang, Di, et al.
Publicado: (2020)

PB2325: VALIDATION OF THE TRAIL SCORE TO PREDICT TOXICITY IN PATIENTS WITH DLBCL RECEIVING R-CHOP-LIKE THERAPY
por: Caballero, Juan Carlos, et al.
Publicado: (2023)

Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
por: Martin, Peter, et al.
Publicado: (2022)

PB2134: THE ROLE OF ADDITIONAL CARBOGEN GAS MIXTURE AND NICOTINAMIDE ON R-CHOP CHEMOTHERAPY IN DLBCL PATIENTS WITH TUMOR HYPOXIA
por: Rizky, D., et al.
Publicado: (2022)

P1219: ZANUBRUTINIB, LENALIDOMIDE PLUS R-CHOP (ZR2-CHOP) AS THE FIRST-LINE TREATMENT FOR NON-GCB DIFFUSED LARGE B-CELL LYMPHOMA (DLBCL)
por: Zhu, H., et al.
Publicado: (2022)

Rituximab exposure‐response in triweekly R‐CHOP treatment in DLBCL: A loading dose is recommended to improve clinical outcomes
por: Liu, Shu, et al.
Publicado: (2021)

Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
por: Belada, David, et al.
Publicado: (2023)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial
por: Johnson, Peter W. M., et al.
Publicado: (2023)

No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study
por: Geerdes, Emma E., et al.
Publicado: (2023)

PB2301: OPTIMAL DOSE INTENSITY OF R-CHOP FOR PATIENTS WITH DLBCL AGED 80 YEARS OR OLDER: IS THE R-MINICHOP A GOLD STANDARD?
por: Nukariya, Hironao, et al.
Publicado: (2023)

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
por: Peroja, Pekka, et al.
Publicado: (2018)

P1196: ORIENT STUDY: REGIMEN OF ORELABRUTINIB PLUS R-CHOP-LIKE FOR PATIENTS WITH NEWLY DIAGNOSED UNTREATED NON-GCB DLBCL
por: Qu, Chang-Ju, et al.
Publicado: (2023)

PB2170: HIGH EXPRESSION OF AP2M1 CORRELATES WITH WORSE PROGNOSIS BY REGULATING IMMUNE MICROENVIRONMENT AND DRUG RESPONSE TO R-CHOP IN DLBCL
por: Liu, X.-D., et al.
Publicado: (2022)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

PB2362: THE EFFECT OF BODY MASS INDEX (BMI) ON THE PROGNOSIS OF DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE
por: el Filali, Imane Ait, et al.
Publicado: (2023)

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
por: Olszewski, Adam J., et al.
Publicado: (2023)

A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution
por: Huang, Jia-Jia, et al.
Publicado: (2016)

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
por: Devi, Kanta, et al.
Publicado: (2021)

P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL
por: Gao, Yan, et al.
Publicado: (2023)

PB2128: CELL OF ORIGIN ACCORDING TO HANS LOGARITHM IS AN INDEPENDENT RISK FACTOR FOR DLBCL PATIENTS TREATED WITH R-CHOP: A REAL WORLD MOROCCAN EXPERIENCE
por: Mahtat, E. M., et al.
Publicado: (2022)

The H/R FcγRIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population
por: Levy, Débora, et al.
Publicado: (2011)

P1185: ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY.
por: Li, C., et al.
Publicado: (2022)

Treating Early-Stage DLBCL on the FLYER: What Lesson for Radiation Therapy?
por: Sokol, Kelsey, et al.
Publicado: (2021)

R-CHOP-Associated Graves' Hyperthyroidism
por: Mora, Natalie, et al.
Publicado: (2019)

P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY
por: Minson, Adrian, et al.
Publicado: (2023)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rmao0i5n165hbu2bm2kfpir5h5